Project Grant R50CA282101
- The National Cancer Institute (NCI) awarded a $717,786 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant will fund a 5-year randomized clinical trial to evaluate the efficacy of the "Supporting Medication Management with Individualized Treatment" (SUMMIT) intervention in improving medication adherence among adolescents and young adults (AYAs) with cancer. SUMMIT is a personalized...
- This $135,949 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to address two critical barriers to enrolling patients in precision medicine clinical trials for acute myeloid leukemia (AML). The award will fund: Developing the capability for rapid in-house molecular testing for all AML patients to enable enrollment in precision medicine trials, and Implementing community and patient education programs to improve awareness and access to AML...
- The University of Chicago was awarded a $361,807 Project Grant by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to tailor and pilot a technology-assisted cognitive behavioral therapy (TCBT) program for adolescents and young adults (AYAs) with hematological malignancies. The grant, titled "Tailoring a Fun and Engaging Tech-Assisted Cognitive Behavioral Therapy Program for Adolescents and Young Adults with Hematological Malignancies: A Planning Grant", aims to...
- This $575,051 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support the University of Arizona Cancer Center's (UACC) efforts to grow its clinical research enterprise and increase diversity in NCI-funded clinical trials over the next 5 years. Key products and services to be delivered include: Expanding UACC's clinical trial portfolio to better serve the diverse populations in its catchment area, particularly Hispanic and Native American...
- The National Cancer Institute (NCI) awarded a $833,467 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Dana-Farber Cancer Institute, Inc. (Dfci) to develop and deploy open-source AI tools to improve cancer clinical trial feasibility and recruitment. The project, called ACTIVATE (AI-Driven Clinical Trial Information and Viability Assessment Tool for EHRs), aims to build on Dfci's existing MatchMiner tool to match patients to trials based on molecular and...
- The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded a Project Grant of $651,859 to the Ann & Robert H. Lurie Children's Hospital of Chicago on Sep 19, 2025. The grant will fund the "#AYAOSM: An Influencer-Driven Social Media Intervention for Oral Chemotherapy Adherence" project, which aims to address suboptimal oral chemotherapy adherence among adolescents and young adults (AYAs) with acute lymphoblastic leukemia. The...
- This $162,486 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate how T-cell acute lymphoblastic leukemia (T-ALL) cells infiltrate the central nervous system (CNS), specifically the meninges, in children with acute lymphoblastic leukemia (ALL). The research aims to address two key questions: 1) whether T-ALL cells traffic through bridging channels in the calvaria (skull) to seed the meninges, and 2) whether...
- The National Cancer Institute (NCI) awarded a $703,321 Cooperative Agreement on September 8, 2025 to Kaiser Foundation Hospitals under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award will support the adaptation and implementation of an evidence-based patient navigation intervention for adolescent and young adult (AYA) cancer survivors over a 2-year project period ending August 31, 2027. The project aims to improve coordination of care, including surveillance for...
- This $3,480,276.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL) in order to identify genetic predictors of relapse and therapeutic vulnerabilities. The principal investigators at Seattle Children's Hospital, a leading pediatric research and healthcare...
- This is a Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Emory University to develop and test an algorithm-enabled intervention called A-PACT (Algorithm-Enabled Patients Activated in Cancer Care Through Teams). The $708,091 grant aims to automate the identification of high-risk cancer patients who need urgent goals of care conversations, and then deliver a structured telephonic intervention by lay health workers to increase these...
CLOSING THE ADOLESCENT AND YOUNG ADULT CLINICAL TRIAL ENROLLMENT GAP WITH AN AYA (ALERT, YOUNG ADULT NAVIGATION AND ALLIANCE) CLINICAL TOOL - PROJECT SUMMARY MORE THAN 80,000 ADOLESCENTS AND YOUNG ADULTS (AYAS, AGES 15- 39 YEARS) ARE DIAGNOSED ANNUALLY WITH CANCER IN THE UNITED STATES, BUT RELATIVELY FEW ENROLL ON CANCER CLINICAL TRIALS (CCTS). LIMITED AYA PARTICIPATION ON CCTS HINDERS THE ABILITY TO FURTHER IMPROVE AYA CANCER CARE AND OUTCOMES. INITIATIVES TO INCREASE AYA CCT ENROLLMENT IS URGENTLY NEEDED. THIS PROPOSAL IDENTIFIES SEVERAL AREAS FOR IMPROVEMENT THAT ARE IMMEDIATELY ADDRESSABLE AND SHAREABLE WITHIN THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER (SKCCC), OTHER MEDICAL CENTERS, AND NCI CONSORTIUM GROUPS. THE APPROACH WILL SIGNIFICANTLY IMPROVE AYA CLINICAL TRIAL PARTICIPATION AT SKCCC BY FURTHER DEVELOPING AND IMPLEMENTING A CLINICAL TRIAL TOOL WE ABBREVIATE AYA: ALERT, YOUNG ADULT NAVIGATION, ALLIANCE, INITIALLY WITHIN THE HEMATOLOGIC MALIGNANCIES (HM)/PEDIATRIC BMT PROGRAM AND THEN BEYOND. THESE INTERVENTIONS WILL CROSS FERTILIZE COLLABORATION AT THREE LEVELS: 1) PATIENT; 2) MULTI-DISCIPLINARY PROVIDER AND 3) CENTER/SYSTEMS. THE SOLUTIONS PROPOSED WILL IMPROVE AYA ACCESS TO AND ENROLLMENT ON CCTS, STRENGTHEN THE CLINICAL RESEARCH ENTERPRISE, AND ADDRESS CANCER DISPARITIES - ALL NCI PRIORITIES. THIS PROPOSAL WILL UTILIZE A NEW MULTI-FACETED ALERT SYSTEM THAT INCLUDES AN ELECTRONIC MEDICAL RECORD (EMR) ALERT TO IDENTIFY AYA PATIENTS AND THE POTENTIAL CLINICAL TRIALS FOR WHICH THEY ARE ELIGIBLE. WEEKLY CLINICAL TRIAL RESEARCH MEETINGS WILL ALERT THE MULTI-DISCIPLINARY TEAM TO THE AYA CLINICAL TRIAL PRIORITY LIST. PATIENT ALERTS VIA OUR EMR DIRECTLY LINKED TO THE PATIENT'S MOBILE DEVICE WILL HIGHLIGHT CCT ENROLLMENT AND UPCOMING APPOINTMENTS. AUTOMATING THE IDENTIFICATION OF TRIAL ELIGIBLE AYA PATIENTS, PROVIDING TIMELY INFORMATION TO THE STUDY TEAM AND PHYSICIANS, AND KEEPING AYA PATIENTS ENGAGED THROUGH EMR DIRECTED MOBILE PHONE MESSAGING WILL OPTIMIZE ENROLLMENT AND COMPLIANCE. A DEDICATED CLINICAL RESEARCH NURSE YOUNG ADULT NAVIGATOR WILL INTERACT EARLY WITH AYA PATIENTS, HELP WITH AYA CCT ENROLLMENT, AND BRIDGE THE KNOWLEDGE AND WORKFLOW GAP BETWEEN OUR ADULT AND PEDIATRIC CONSORTIUM TRIALS. A COHORT OF PRIOR AYA CCT PARTICIPANT SURVIVOR NAVIGATORS WILL SERVE AS SPOKESPEOPLE ON OUR AYA WEBSITE AND ON SOCIAL MEDIA. AN AYA PSYCHOSOCIAL NAVIGATOR WILL ROUND OUT THE PARTNERSHIP TO IMPROVE AYA SUPPORT. LASTLY, A MULTI-FACETED EDUCATION CAMPAIGN WILL BE LAUNCHED TO IMPROVE ALLIANCES. NCI- CONSORTIUM ENROLLMENT ISSUES WILL BE HIGHLIGHTED AT JOINT HM/PEDIATRIC BMT CLINICAL RESEARCH MEETINGS. WE WILL CREATE CROSS-NETWORK ENROLLMENT FAQ DOCUMENTS. USING DIGITAL COMMUNICATION, WE WILL PROVIDE INFORMATION TO AYAS ABOUT CCTS TO SUPPLEMENT DISCUSSIONS WITH PROVIDERS. WE WILL EXTEND THE ONGOING PROJECTS INITIATED BY THE DIVERSITY AND INCLUSION IN CLINICAL RESEARCH PROGRAM AT SKCCC TO INCLUDE AN AYA PATIENT FOCUS TO OPTIMIZE THE ENROLLMENT OF UNDERSERVED MINORITIES. BEST PRACTICES IDENTIFIED FROM THIS PROJECT WILL BE READILY TRANSFERRABLE TO THE ENTIRE SKCCC ENTERPRISE AND OTHER ACADEMIC MEDICAL CENTERS. AS A NATIONALLY RECOGNIZED BMT EXPERT WITH A STRONG COMMITMENT TO NCI-FUNDED CLINICAL TRIALS AND EXTENSIVE KNOWLEDGE IN CLINICAL RESEARCH OPERATIONS, DR. SYMONS IS POISED TO LEAD THESE EFFORTS AND SUCCESSFULLY ENHANCE AYA ACCRUALS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $167.0k | 8/26/25 | ||
| Not listed | $167.0k | 8/20/24 |